Etatsizin - instructions for use, reviews, analogs and form of release (tablets 50 mg) antiarrhythmic drug for the treatment of tachycardia, extrasystole and other arrhythmias in adults, children and pregnancy. Composition and alcohol

In this article, you can read the instructions for using the drug Etatsizin. Presented are reviews of visitors to the site - consumers of this medication, as well as opinions of doctors of specialists on the use of Etatsizina in their practice. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Analogues of Etatsizin in the presence of existing structural analogues. Use for the treatment of tachycardia, extrasystole and other arrhythmias in adults, children,as well as during pregnancy and lactation. Composition and interaction of the drug with alcohol.

Etatsizin - antiarrhythmic drug class 1C. Has a long antiarrhythmic effect. Oppresses the rate of rise of the action potential front (Vmax), does not change the rest potential.

Depending on the dose, it can reduce the duration of the action potential. It does not significantly change the effective refractory periods of the ventricles and atria. Inhibits the rapid incoming sodium current and, to a lesser extent, the slow incoming calcium current.

Etatsizin slows down the excitation of the conduction system of the myocardium. On the ECG appears an extension of the PR interval and the QRS complex; the ST interval, reflecting the repolarization of the ventricles, does not change or tends to be shortened.

Etatsizin increases the threshold of myocardial fibrillation. Unlike many antiarrhythmic drugs, Etatsizin does not cause a significant decrease in heart rate or prolongation of the QT interval on the ECG.

Antiarrhythmic effect with ingestion usually develops on 1-2 days, the duration of treatment depends on the form of arrhythmia, efficacy and tolerability of the drug.

Composition

Diethylaminopropionylethoxycarbonylaminophenothiazine hydrochloride (ethacyzin) + auxiliary substances.

Pharmacokinetics

When ingested, the drug is rapidly absorbed from the digestive tract and is determined in the blood after 30-60 minutes. Bioavailability - 40%. Binding to plasma proteins is about 90%. Etatsizin penetrates the placental barrier. Excreted in breast milk. Intensively metabolized when the "first pass" through the liver. Some of the metabolites that are formed have antiarrhythmic activity. From the body, the active substance is excreted in the urine in the form of metabolites.

Indications

• supraventricular and ventricular extrasystole;
• paroxysms of flicker and atrial flutter;
• ventricular and supraventricular tachycardia (including and with WPW syndrome).

Forms of release

The tablets covered with a cover of 50 mg.

Instructions for use and dosage

The drug should be taken inside regardless of food intake, 50 mg 2-3 times a day.

In case of insufficient clinical effect, the dose is increased (under compulsory ECG monitoring) to 50 mg 4 times a day (200 mg) or 100 mg 3 times daily (300 mg).

When a persistent antiarrhythmic effect is achieved, maintenance therapy is performed inindividually selected minimum effective doses.

Side effect

• stopping the sinus node;
• AV blockade;
• violation of intraventricular conduction;
• decreased myocardial contractility;
• decreased coronary blood flow;
• arrhythmia;
• changes on ECG (prolongation of PQ interval, extension of P wave and QRS complex);
• arrhythmogenic effect, the probability of which is greatest after a myocardial infarction and in other types of cardiac pathology, leading to a decrease in the contractility of the heart muscle and the development of heart failure;
• dizziness;
• headache;
• swaying when walking or turning the head;
• slight drowsiness;
• diplopia;
• paresis of accommodation;
• nausea.

Side effects depend on the size of the dose and, to avoid them, do not prescribe the maximum dose of the drug.

Contraindications

• marked conduction disorders (including sinoatrial block, AV blockade of 2 and 3 degrees in the absence of an artificial pacemaker), violation of intraventricular conduction;
• heart rhythm disturbances in combination with blockages of the Guis system - Purkinje fibers;
• severe left ventricular myocardial hypertrophy;
• presence of postinfarction cardiosclerosis;
• cardiogenic shock;
• severe arterial hypotension;
• chronic heart failure 2 and 3 functional class according to NYHA classification;
• severe impairment of liver and / or kidney function;
• simultaneous administration of MAO inhibitors;
• simultaneous administration with antiarrhythmic drugs of class 1C (propafenone, allapinin) and class 1A (quinidine, procainamide, disopyramide, aymalin);
• age under 18 years (effectiveness and safety not established);
• pregnancy;
• lactation period (breastfeeding);
• hypersensitivity to the components of the drug.

Application in pregnancy and lactation

Contraindicated use of the drug Etatsizin during pregnancy and lactation (breastfeeding).

Penetrates through the placental barrier. Excreted in breast milk. Limited use of the drug when breastfeeding.

Use in children

Contraindicated in children and adolescents under the age of 18 years (efficacy and safety not established).

special instructions

Like other antiarrhythmic drugs, Etatsizin can act arrhythmogenically. Therefore, in the appointment of Etatsizin follows:

• strictly take into account contraindications to the use of the drug;
• in advance to reveal and eliminate hypokalemia;
• avoid using Etatsizina in combination with antiarrhythmics drugs class 1A and class 1C;
• it is preferable to begin course treatment in a hospital (especially in the first 3-5 days of taking the drug, taking into account the ECG dynamics after trial and repeated doses of Etatsizina or ECG monitoring data);
• stop treatment with increased ectopic ventricular complexes, blockades or bradycardia;
• stop treatment with ventricular complex expansion by more than 25%, decrease in their amplitude, the duration of the P wave on the ECG is more than 0.12 seconds.

Risk factors for arrhythmogenic effects of Etatsizina: organic damage to the heart (especially myocardial infarction), reduction of the left ventricular ejection fraction, maximum dose of the drug. In addition, caution should be exercised in patients with liver disease.

When treating Etatsizinom you should not drink alcohol.

During therapy, the patient's condition and cardiovascular function (blood pressure, ECG, echocardiography) must be regularly monitored.

Impact on the ability to drive vehicles and manage mechanisms

Because of the risk of developing dizziness, it is not recommended to drive vehicles or service complex mechanisms that require increased attention, ability to concentrate.

Drug Interactions

Contraindicated the use of etatsizina with other antiarrhythmic drugs class 1C (propafenone, allapinin) and class 1A (quinidine, procainamide, disopyramide, aymalin).

Etatsizin should not be administered simultaneously with MAO inhibitors.

The combination of beta-blockers with Etatsizin increases the antiarrhythmic effect, especially in relation to arrhythmias, provoked by physical exertion or stress.

Analogues of the drug Etatsizin

Structural analogues for the active substance medicine Etatsizin has not.

Analogues on the pharmacological group (antiarrhythmic drugs):

• Adenocorus;
• Allapinin;
• Amiodarone;
• Amiocordin;
• Asparks;
• Bretilate;
• Hypertonplant (Gnafalin);
• Hypertonplant Phytotea;
• Dinexan;
• Diphenine;
• Cardiodarone;
• Kinidin Durules;
• Cordarone;
• Lappakonitina hydrobromide;
• Lidocaine;
• Lidocaine hydrochloride;
• Multac;
• Neo Giluritmal;
• Nibentan;
• Novocaineamide;
• Opakorden;
• Pamaton;
• Panangin;
• Panangin Forte;
• Piperidyl nitrobenzamide hydrochloride;
• Procainamide;
• Propanorm;
• Propaphenone;
• Profen;
• Refralon;
• Ritalmex;
• Rhythmiodaron;
• Rhythmodan;
• Rhythm monm;
• Sedacorone;
• Trimecaine;
• Ethmosin.

Similar medicines:

Other medicines: